Tragara Pharmaceuticals is focusing its development efforts
on three NCEs and 1 companion diagnostic:
Capoxigem® (apricoxib, TG01) for the treatment of solid
tumors and inflammation-related disorders;
TG02, a novel small molecule that blocks, within a narrow
potency range, major signaling pathways involving JAK2,
FLT3, ERK5 and key cell cycle and transcriptional regulatory
cyclin-dependent kinases (CDKs), with excellent pharmacological
and pharmaceutical properties, and the flexibility of oral
administration. The kinase pathways modulated by TG02 drive
disease progression and survival in hematologic malignancies
and solid tumors;
TG03, a combination product of Capoxigem and an EGFR-TKI;
ProGEM™, our proprietary diagnostic being developed
as a companion to Capoxigem, designed to execute our personalized
medicine strategy.
